Algenpantucel-L immunotherapy in pancreatic adenocarcinoma

Immunotherapy
Andrew L CovelerE Gabriela Chiorean

Abstract

Pancreatic adenocarcinoma is the 4th leading cause of cancer death in the USA and the EU. A minority of patients presents with surgically resectable and potentially curable disease, but among these, 80% are destined to relapse and overall survival rates with adjuvant chemotherapy average 24 months. Immunotherapy is a promising therapeutic option and a potential paradigm shift in the treatment of patients with pancreatic cancer, and may be particularly effective when used early in the disease course to prevent metastatic spread. Algenpantucel-L (HyperAcute Pancreas, NewLink Genetics, Ames, IA, USA) is a whole-cell immunotherapy consisting of irradiated allogeneic pancreatic cancer cells genetically engineered to express the murine enzyme α-GT, which results in hyperacute rejection of the tumor cells with complement- and antibody-dependent cytotoxicity. Phase II clinical trial data has been encouraging, particularly for patients who demonstrated humoral immunologic responses. Here, we report preliminary results and biomarkers correlations with clinical activity of algenpantucel-L in pancreatic cancer.

References

Jun 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H A BurrisD D Von Hoff
Sep 27, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Nobuyoshi HiraokaSetsuo Hirohashi
Dec 26, 2006·Nature Medicine·Michel ObeidGuido Kroemer
Nov 26, 2010·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Stefania RossiAlessandro Fanzani
Apr 6, 2011·Immunotherapy·Lindzy F DodsonPeter Goedegebuure
May 13, 2011·The New England Journal of Medicine·Thierry ConroyUNKNOWN PRODIGE Intergroup
Oct 5, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Patrick J LoehrerAl B Benson
Aug 17, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Christine FeigDavid A Tuveson
Dec 12, 2012·Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract·Jeffrey M HardacreE Gabriela Chiorean
Oct 10, 2013·JAMA : the Journal of the American Medical Association·Helmut OettleHanno Riess
Oct 18, 2013·The New England Journal of Medicine·Daniel D Von HoffMarkus F Renschler
Feb 7, 2014·International Journal of Cancer. Journal International Du Cancer·Katia NonesSean M Grimmond
Jan 7, 2015·CA: a Cancer Journal for Clinicians·Rebecca L SiegelAhmedin Jemal
Jan 15, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Dung T LeElizabeth M Jaffee
Jan 15, 2015·Human Vaccines & Immunotherapeutics·Marion L HartleyJohn L Marshall
Mar 10, 2015·Frontiers in Oncology·Marco de BruynEdwin Bremer
Mar 11, 2015·Therapeutic Advances in Medical Oncology·Andrea TeagueAndrea Wang-Gillam

❮ Previous
Next ❯

Citations

Nov 20, 2019·The Oncologist·Suneel D KamathMary Mulcahy
Jun 2, 2016·American Society of Clinical Oncology Educational Book·Andrew L CovelerE Gabriela Chiorean
Mar 7, 2020·Digestive Diseases and Sciences·Jia Wu, Jianting Cai
Mar 30, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Erik S KnudsenAgnieszka K Witkiewicz
Jan 21, 2019·Gastroenterology·Vinod P BalachandranStephanie K Dougan
Jul 3, 2021·Vaccines·Howard DonningerKavitha Yaddanapudi

❮ Previous
Next ❯

Methods Mentioned

BETA
surgical resection

Clinical Trials Mentioned

NCT01964430
NCT02054520
NCT01072981
NCT01836432
NCT02405585

Related Concepts

Related Feeds

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.

Antibody-Dependent Cell Cytotoxicity

Antibody-dependent cellular toxicity refers to the lysis of a target cell by a non-sensitized effector cell of the immune system as a result of antibodies binding to the target cell membrane and engaging the Fc receptors on the immune effector cells. Find the latest research on antibody-dependent cellular toxicity here.

Related Papers

Human Vaccines & Immunotherapeutics
Kinsey A McCormickE Gabriela Chiorean
Nature Clinical Practice. Gastroenterology & Hepatology
Bert H O'Neil, Richard M Goldberg
JAMA : the Journal of the American Medical Association
Patrick Maisonneuve, Albert B Lowenfels
JAMA : the Journal of the American Medical Association
Anand T Shivnani
© 2022 Meta ULC. All rights reserved